Comparison of predictive accuracy for pathologically organ confined clinical stage T1c prostate cancer using human glandular kallikrein 2 and prostate specific antigen combined with clinical stage and Gleason grade.

Comparison of predictive accuracy for pathologically organ confined clinical stage T1c prostate cancer using human glandular kallikrein 2 and prostate specific antigen combined with clinical stage and Gleason grade.

PURPOSE: Previously human glandular kallikrein 2 (hK2) has been implicated to predict pathologically organ confined prostate cancer (PCa) in patients with stage T2 disease. Now we evaluated the usefulness of hK2, as measured by 2 entirely different immunoassay designs, to enhance the discrimination...

Descripció completa

Dades bibliogràfiques
Autors principals:	Haese, A, Vaisanen, V, Lilja, H, Kattan, M, Rittenhouse, H, Pettersson, K, Chan, D, Huland, H, Sokoll, L, Partin, A
Format:	Journal article
Idioma:	English
Publicat:	2005

Ítems similars

Standardization of two immunoassays for human glandular kallikrein 2.
per: Haese, A, et al.
Publicat: (2003)

The role of human glandular kallikrein 2 for prediction of pathologically organ confined prostate cancer.
per: Haese, A, et al.
Publicat: (2003)

Association of free-prostate specific antigen subfractions and human glandular kallikrein 2 with volume of benign and malignant prostatic tissue.
per: Steuber, T, et al.
Publicat: (2005)

Human glandular kallikrein 2: a potential serum marker for predicting the organ confined versus non-organ confined growth of prostate cancer.
per: Haese, A, et al.
Publicat: (2000)

Human glandular kallikrein 2 levels in serum for discrimination of pathologically organ-confined from locally-advanced prostate cancer in total PSA-levels below 10 ng/ml.
per: Haese, A, et al.
Publicat: (2001)

Comparison of free and total forms of serum human kallikrein 2 and prostate-specific antigen for prediction of locally advanced and recurrent prostate cancer.
per: Steuber, T, et al.
Publicat: (2007)

Testing in serum for human glandular kallikrein 2, and free and total prostate specific antigen in biannual screening for prostate cancer
per: Becker, C, et al.
Publicat: (2003)

Testing in serum for human glandular kallikrein 2, and free and total prostate specific antigen in biannual screening for prostate cancer.
per: Becker, C, et al.
Publicat: (2003)

Total and gleason grade 4/5 cancer volumes are major contributors of human kallikrein 2, whereas free prostate specific antigen is largely contributed by benign gland volume in serum from patients with prostate cancer or benign prostatic biopsies
per: Haese, A, et al.
Publicat: (2003)

Total and Gleason grade 4/5 cancer volumes are major contributors of human kallikrein 2, whereas free prostate specific antigen is largely contributed by benign gland volume in serum from patients with prostate cancer or benign prostatic biopsies.
per: Haese, A, et al.
Publicat: (2003)

Simultaneous quantification of human glandular kallikrein 2 and prostate-specific antigen mRNAs in peripheral blood from prostate cancer patients.
per: Ylikoski, A, et al.
Publicat: (2001)

Risk assessment for biochemical recurrence prior to radical prostatectomy: significant enhancement contributed by human glandular kallikrein 2 (hK2) and free prostate specific antigen (PSA) in men with moderate PSA-elevation in serum.
per: Steuber, T, et al.
Publicat: (2006)

Intact free prostate-specific antigen and free and total human glandular kallikrein 2. Elimination of assay interference by enzymatic digestion of antibodies to F(ab')2 fragments.
per: Väisänen, V, et al.
Publicat: (2006)

Taxon-specific evolution of glandular kallikrein genes and identification of a progenitor of prostate-specific antigen.
per: Olsson, A, et al.
Publicat: (2004)

Development of sensitive immunoassays for free and total human glandular kallikrein 2.
per: Väisänen, V, et al.
Publicat: (2004)

Clinical value of human glandular kallikrein 2 and free and total prostate-specific antigen in serum from a population of men with prostate-specific antigen levels 3.0 ng/mL or greater.
per: Becker, C, et al.
Publicat: (2000)

Anti-thrombin is expressed in the benign prostatic epithelium and in prostate cancer and is capable of forming complexes with prostate-specific antigen and human glandular kallikrein 2.
per: Cao, Y, et al.
Publicat: (2002)

Simultaneous quantification of prostate-specific antigen and human glandular kallikrein 2 mRNA in blood samples from patients with prostate cancer and benign disease.
per: Ylikoski, A, et al.
Publicat: (2002)

Prostate-specific antigen and related isoforms in the diagnosis and management of prostate cancer.
per: Haese, A, et al.
Publicat: (2004)

Sensitive and specific immunodetection of human glandular kallikrein 2 in serum.
per: Becker, C, et al.
Publicat: (2000)

Discrimination of men with prostate cancer from those with benign disease by measurements of human glandular kallikrein 2 (HK2) in serum.
per: Becker, C, et al.
Publicat: (2000)

Expression of prostate-specific antigen (PSA) and human glandular kallikrein 2 (hK2) in ileum and other extraprostatic tissues.
per: Olsson, A, et al.
Publicat: (2005)

The role of molecular forms of prostate-specific antigen (PSA or hK3) and of human glandular kallikrein 2 (hK2) in the diagnosis and monitoring of prostate cancer and in extra-prostatic disease.
per: Becker, C, et al.
Publicat: (2001)

[Isoforms of free prostate-specific antigen]
per: Haese, A, et al.
Publicat: (2004)

Isoforms of free prostate-specific antigen
per: Haese, A, et al.
Publicat: (2004)

Time-resolved fluorescence imaging for specific and quantitative immunodetection of human kallikrein 2 and prostate-specific antigen in prostatic tissue sections.
per: Siivola, P, et al.
Publicat: (2000)

Discrimination of benign from malignant prostatic disease by selective measurements of single chain, intact free prostate specific antigen.
per: Steuber, T, et al.
Publicat: (2002)

Screening a combinatorial peptide library to develop a human glandular kallikrein 2-activated prodrug as targeted therapy for prostate cancer.
per: Janssen, S, et al.
Publicat: (2004)

Testosterone as a predictor of pathological stage in clinically localized prostate cancer.
per: Isom-Batz, G, et al.
Publicat: (2005)

Prostate kallikrein markers in diagnosis, risk stratification and prognosis.
per: Ulmert, D, et al.
Publicat: (2009)

The evolution of the glandular kallikrein locus: identification of orthologs and pseudogenes in the cotton-top tamarin.
per: Olsson, A, et al.
Publicat: (2004)

Free-to-total prostate-specific antigen ratio as a predictor of non-organ-confined prostate cancer (stage pT3).
per: Aus, G, et al.
Publicat: (2003)

Similar rates of exponential decrease in serum concentrations of free prostate-specific antigen (PSA), PSA complexed to alpha-1-antichymotrypsin, and human glandular kallikrein 2 (hK2) in prostate cancer patients treated with GnRH-analogues.
per: Björk, T, et al.
Publicat: (2001)

Prostate-specific antigen (PSA) protein does not affect growth of prostate cancer cells in vitro or prostate cancer xenografts in vivo.
per: Denmeade, SR, et al.
Publicat: (2003)

Gleason score 7 prostate cancer on needle biopsy: relation of primary pattern 3 or 4 to pathological stage and progression after radical prostatectomy
per: A Amin, et al.
Publicat: (2011-10-01)

Evaluation of molecular forms of prostate-specific antigen and human kallikrein 2 in predicting biochemical failure after radical prostatectomy.
per: Wenske, S, et al.
Publicat: (2009)

Rapid elimination by glomerular filtration of free prostate specific antigen and human kallikrein 2 after renal transplantation.
per: Bruun, L, et al.
Publicat: (2004)

Correlation between Prostate Specific Antigen and Prostate Biopsy Gleason Score
per: Ngwu PE, et al.
Publicat: (2019-12-01)

Discrimination of prostate cancer from benign disease by selective measurements of serum subfractions of free PSA that are not internally cleaved at Lys145-Lys146
per: Nurmikko, P, et al.
Publicat: (2002)

Free PSA isoforms and intact and cleaved forms of urokinase plasminogen activator receptor in serum improve selection of patients for prostate cancer biopsy.
per: Steuber, T, et al.
Publicat: (2007)